Description
While the approach mentioned identifying therapeutic hypotheses from aging gene expression data, no specific targets were evaluated for druggability or therapeutic tractability. This represents a major gap between discovery and translation.
Source: Debate session sess_SDA-2026-04-02-gap-aging-mouse-brain-v4-20260402 (Analysis: SDA-2026-04-02-gap-aging-mouse-brain-v4-20260402)
Resolution criteria
Resolution requires: (1) systematic druggability assessment of >=50 aging-associated genes (from Aging Hallmarks or GWAS) using structure-based AI screening (AlphaFold, ESMFold) for binding site druggability scores >=0.7; (2) experimental validation of top 10 candidates in iPSC-derived neurons measuring target engagement (CETSA or DARTS) and functional outcome (synaptic activity, tau/AT8 pathology); (3) in vivo efficacy testing in aged AD mouse models (>=12 months old) for top 3 candidates with >=30% improvement in cognitive readouts and acceptable safety profile. Target identification without experimental validation of druggability and in vivo efficacy is insufficient.